Imagion Biosystems Limited (ASX: IBX) (Imagion or the Company) is pleased to announce a pro-rata non- renounceable rights issue (Offer) to shareholders, on the basis of 1 new share for every 2 Imagion shares held as at 7.00pm (Melbourne time) Friday 28 September 2018 (Record Date).
View the Pro-Rata Non-Renounceable Rights Issue announcement.
Quarterly Activity Report – Quarter ending 31 December 2023
January 31, 2024
Highlights: Announced positive results from IBI10103 Phase I Study demonstrating safety and clinical feasibility of molecular MRI with MagSense® HER2 Imaging Agent Presented new animal